Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis-Reference-Cited by-同舟云学术

Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis

Published:2018-11-19 Issue:1 Volume:37 Page:85-95
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Konuma Takaaki¹^ORCID,Shimomura Yoshimitsu²,Ozawa Yukiyasu³,Ueda Yasunori⁴,Uchida Naoyuki⁵,Onizuka Makoto⁶,Akiyama Megumi⁷,Mori Takehiko⁸,Nakamae Hirohisa⁹,Ohno Yuju¹⁰,Shiratori Souichi¹¹,Onishi Yasushi¹²,Kanda Yoshinobu¹³^ORCID,Fukuda Takahiro¹⁴,Atsuta Yoshiko¹⁵¹⁶,Ishiyama Ken¹⁷,

Affiliation:

1. Department of Hematology/Oncology, The Institute of Medical ScienceThe University of Tokyo Tokyo Japan

2. Department of HematologyKobe City Hospital Organization, Kobe City Medical Center General Hospital Kobe Japan

3. Department of HematologyJapanese Red Cross Nagoya First Hospital Nagoya Japan

4. Department of Hematology and OncologyKurashiki Central Hospital Kurashiki Japan

5. Department of HematologyFederation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital Tokyo Japan

6. Department of Hematology and OncologyTokai University School of Medicine Isehara Japan

7. Hematology DivisionTokyo Metropolitan Komagome Hospital Tokyo Japan

8. Division of Hematology, Department of MedicineKeio University School of Medicine Tokyo Japan

9. Hematology, Graduate School of MedicineOsaka City University Osaka Japan

10. Department of Internal MedicineKitakyushu Municipal Medical Center Kitakyushu Japan

11. Department of HematologyHokkaido University Hospital Sapporo Japan

12. Department of Hematology and RheumatologyTohoku University Hospital Sendai Japan

13. Division of HematologyJichi Medical University Saitama Medical Center Saitama Japan

14. Department of Hematopoietic Stem Cell TransplantationNational Cancer Centre Hospital Tokyo Japan

15. Japanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan

16. Department of Healthcare AdministrationNagoya University Graduate School of Medicine Nagoya Japan

17. Department of HematologyKanazawa University Hospital Kanazawa Japan

Funder

the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from Japan Agency for Medical Research and Development, AMED

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2566

Reference33 articles.

1. Allogeneic Stem Cell Transplantation for Adults with Myelodysplastic Syndromes: Importance of Pretransplant Disease Burden

2. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen‐identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation‐Chronic Malignancies Working Party;Onida F;Haematologica.,2014

3. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy;Anderson JE;Blood.,1997

4. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome

5. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT;Annals of Hematology;2023-11-08

2. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: A real‐world registry study in Japan;American Journal of Hematology;2023-01-24

3. Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome;Leukemia Research;2023-01

4. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in a prospective observational study: The JALSG-CS11-MDS-SCT;2022-11-18

5. Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study;Annals of Hematology;2022-09-23